Protara Therapeutics, Inc. quarterly report, Q3 FY2015

Business context and reporting period

The supplied filing is Proteon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015, filed November 12, 2015. It does not identify Protara Therapeutics, Inc.; investors should verify the issuer and filing before relying on this summary.

Proteon was a development-stage biopharmaceutical company focused primarily on vonapanitase, a product candidate intended to improve arteriovenous fistula (AVF) patency in patients with chronic kidney disease. It had no product sales and was primarily funded through capital raises.

Financial results and liquidity

Amounts below are in millions of dollars, except per-share data. The filing reports no product revenue for 2015; the 2014 comparative revenue arose from expiration of rights under a prior agreement, not product sales.

At September 30, 2015, cash and cash equivalents were $35.983 million and available-for-sale investments were $34.565 million, totaling $70.548 million. Current assets were $71.377 million and current liabilities $3.168 million. Total liabilities were $3.252 million; the filing reports no outstanding debt balance at quarter-end. Earlier convertible notes had been extinguished in 2014. Accumulated deficit was $124.909 million.

For the first nine months of 2015, operating cash use was $12.380 million, investing cash use was $20.549 million and financing provided $0.101 million. Cash and cash equivalents decreased $32.857 million to $35.983 million; investing cash flows included purchases and maturities or sales of available-for-sale securities, so this decline should be viewed alongside total cash and investments. The filing does not provide a meaningful product gross margin; the company had no product revenue.

Material changes versus the prior comparable period

• First-nine-month net loss widened by $4.460 million to $15.035 million, principally reflecting higher operating expenses and the absence of the $2.948 million 2014 revenue recognition.
• Research and development expense rose $4.243 million year over year, mainly from Phase 3 trial costs and manufacturing pre-validation; general and administrative expense rose $3.185 million, including public-company and personnel costs.
• Other expense was substantially lower than in 2014 because the earlier period included a $5.3 million charge related to Series D investor rights. In 2015, foreign-exchange forward contracts contributed $0.440 million of realized and unrealized losses for the nine-month period.
• Interest expense on convertible notes ceased after their 2014 extinguishment. Nine-month cash used in operations increased $4.440 million year over year.

Outlook, management commentary and risks

• Management estimated existing cash, cash equivalents and investments would fund operations and capital expenditures into the fourth quarter of 2017, supporting first Phase 3 results, enrollment in the second Phase 3 trial and CMC work. This is a forward-looking estimate subject to spending and development risks.
• The company warned that its resources were not expected to fund completion of the second Phase 3 trial. Additional financing or strategic arrangements may be needed, and may not be available on acceptable terms or at all.
• PATENCY-1 completed enrollment in October 2015, after quarter-end; top-line results were expected in December 2016. PATENCY-2 began enrolling in August 2015, with completion expected in the first quarter of 2017.
• A key efficacy risk is that the Phase 2 primary endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. Favorable findings in radiocephalic AVF patients came from analyses not prespecified in the protocol and may not be replicated in Phase 3.
• The company might discuss a BLA based on one Phase 3 trial if results were compelling, but FDA acceptance or approval on that basis was uncertain. Clinical, regulatory, enrollment, manufacturing, safety, reimbursement, intellectual-property and third-party execution risks were prominent.
• Vonapanitase API manufacturing was contracted to Lonza, with payments denominated in Swiss francs. The company used foreign-currency forwards but did not apply hedge accounting, so fair-value changes affected earnings. It also entered a Lonza manufacturing services agreement in 2015.
• Management reported effective disclosure controls at the reasonable-assurance level and no material change in internal control over financial reporting during the nine months. No material legal proceeding was reported.

Important facts for investors to verify

• Confirm that the filing is for Proteon Therapeutics, not Protara Therapeutics, and verify the intended issuer and period.
• Check subsequent filings for PATENCY-1 results, PATENCY-2 enrollment and timing, and any FDA guidance on a potential single-trial BLA.
• Reassess cash runway against actual operating cash use, trial and CMC spending, and the funding required to complete the second Phase 3 trial.
• Review foreign-exchange exposures and losses, manufacturing dependence on Lonza and other contractors, and any changes to supply or trial plans.
• Monitor clinical efficacy and safety, regulatory requirements, potential dilution or financing terms, and whether the stated runway assumptions remain valid.